RU2007143510A - Инсулиновые композиции - Google Patents

Инсулиновые композиции Download PDF

Info

Publication number
RU2007143510A
RU2007143510A RU2007143510/15A RU2007143510A RU2007143510A RU 2007143510 A RU2007143510 A RU 2007143510A RU 2007143510/15 A RU2007143510/15 A RU 2007143510/15A RU 2007143510 A RU2007143510 A RU 2007143510A RU 2007143510 A RU2007143510 A RU 2007143510A
Authority
RU
Russia
Prior art keywords
insulin
betaine
pharmaceutical association
combination according
administration
Prior art date
Application number
RU2007143510/15A
Other languages
English (en)
Russian (ru)
Inventor
Яллал МЕССАДЕК (BE)
Яллал МЕССАДЕК
Original Assignee
Яллал МЕССАДЕК (BE)
Яллал МЕССАДЕК
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яллал МЕССАДЕК (BE), Яллал МЕССАДЕК filed Critical Яллал МЕССАДЕК (BE)
Publication of RU2007143510A publication Critical patent/RU2007143510A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2007143510/15A 2005-04-27 2006-04-27 Инсулиновые композиции RU2007143510A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BEPCT/BE2005/000061 2005-04-27
BEPCT/BE2005/000061 2005-04-27

Publications (1)

Publication Number Publication Date
RU2007143510A true RU2007143510A (ru) 2009-06-10

Family

ID=37215100

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007143510/15A RU2007143510A (ru) 2005-04-27 2006-04-27 Инсулиновые композиции

Country Status (10)

Country Link
US (1) US7786077B2 (enExample)
EP (1) EP1885392B1 (enExample)
JP (1) JP2009506978A (enExample)
CN (1) CN101180073A (enExample)
AT (1) ATE540690T1 (enExample)
BR (1) BRPI0610249A2 (enExample)
CA (1) CA2650556A1 (enExample)
MX (1) MX2007013486A (enExample)
RU (1) RU2007143510A (enExample)
WO (1) WO2006113978A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
ES2450148T3 (es) * 2008-06-26 2014-03-24 Laboratorios Silanes, S.A. De C.V. Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
US10143754B2 (en) * 2011-08-07 2018-12-04 Transgene Biotek Limited Method for peroral delivery of insulin and its analogues for therapeutic usage
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISOR FOR DIABETES MANAGEMENT

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2590M (fr) 1963-03-12 1964-06-15 Albert Beaufour Nouvelles associations antinévralgiques a tolérance améliorée.
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
FR2119889A1 (en) 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
GB1509979A (en) 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
FR2403799A2 (fr) 1977-09-27 1979-04-20 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
US4605548A (en) * 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
PL149493B1 (en) * 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US4902718A (en) * 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
MC2041A1 (fr) 1988-06-24 1990-05-30 Johannes Cornelius Str Andries Agents anti-atherogenic
IT1226386B (it) 1988-07-08 1991-01-15 Chiesi Farma Spa Procedimento di preparazione di morniflumato e analoghi.
US4968719A (en) 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
WO1995015750A1 (en) 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
US6355166B1 (en) * 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
JP3234113B2 (ja) * 1994-11-11 2001-12-04 日本甜菜製糖株式会社 血糖値上昇抑制剤及び利用
US5961999A (en) 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
JP3119430B2 (ja) 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
US6162926A (en) 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
LV11727B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
AU2260397A (en) * 1996-01-31 1997-08-22 Trustees Of The University Of Pennsylvania, The Remote control drug delivery device
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
SE9601395D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP3174013B2 (ja) 1997-05-15 2001-06-11 コビシ電機株式会社 シール式センサ
US6258859B1 (en) 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
CA2322824A1 (en) 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
JP5220968B2 (ja) 1998-10-30 2013-06-26 ヨーロピアン ブランド パティスィペイションズ エス ア 心臓血管疾患の治療および予防のための組成物
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
DE19910682B4 (de) 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
BE1012546A6 (fr) 1999-03-10 2000-12-05 Messadek Jallal La betaine et ses derives pour leur usage antithrombotique.
BE1012712A6 (fr) 1999-06-10 2001-02-06 Messadek Jallal Peptides antithrombotiques.
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
AU2001268722B8 (en) 2000-06-23 2005-09-29 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
WO2002047493A2 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Health promoting compositions
FI114538B (fi) 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
DK1408949T3 (da) 2001-02-05 2008-04-28 Jallal Messadek Glycinbetain og dets brugområde for opfindelsen
AU2002257582A1 (en) 2001-02-14 2002-09-04 Glaxo Wellcome S.A. Pharmaceutical formulation
US20040072750A1 (en) * 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US20030054978A1 (en) * 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
US20060160896A1 (en) 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2003078960A2 (en) * 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
ES2364155T3 (es) 2002-11-25 2011-08-25 Jallal Messadek Composiciones de betaína y ácido acetilsalicílico.
ES2278314T3 (es) 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
US7097968B2 (en) * 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
CA2575760A1 (en) 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
US20060128657A1 (en) 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
EP1663174A1 (en) 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
BE1016128A6 (fr) 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use

Also Published As

Publication number Publication date
US7786077B2 (en) 2010-08-31
ATE540690T1 (de) 2012-01-15
MX2007013486A (es) 2008-03-14
EP1885392A2 (en) 2008-02-13
CN101180073A (zh) 2008-05-14
US20080214441A1 (en) 2008-09-04
WO2006113978A2 (en) 2006-11-02
WO2006113978A3 (en) 2007-03-22
BRPI0610249A2 (pt) 2010-06-08
CA2650556A1 (en) 2006-11-02
JP2009506978A (ja) 2009-02-19
EP1885392B1 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
RU2007143510A (ru) Инсулиновые композиции
US7879909B2 (en) Use of Treprostinil to treat neuropathic diabetic foot ulcers
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
KR20110085985A (ko) 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
RU2012124069A (ru) Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
JPH06504286A (ja) 人ｉｇｆ−ｉの利用方法
KR20130139297A (ko) 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
CN115947822B (zh) 一种长效酰化胰岛素衍生物及其药物组合物和应用
JP2009506978A5 (enExample)
JP2004518756A (ja) Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
JP2006527234A5 (enExample)
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
KR20250029908A (ko) 티르제파티드 조성물 및 용도
CN108703946A (zh) 一种治疗糖尿病周围神经痛的透皮吸收制剂
TW202423476A (zh) 含腸促胰島素(incretin)類似物之組合物及其用途
WO2021143879A1 (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
EP1317308A2 (en) Reduction of the electrocardiographic ot interval
AU2001286092A1 (en) Reduction of the electrocardiographic OT interval
US20140249122A1 (en) Anti-diabetic aminosteroid derivatives
CA3166027A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
WO2025068976A1 (en) Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
WO2024261580A1 (en) Glp-1 analog for use in the treatment of metabolic disorders
BR102014006730A2 (pt) métodos terapêuticos e composições para tratamento de diabetes

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100820